Drugs / CAR-DC
CAR-DC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07504445 | Jun 2026 → Apr 2028 expected | cancer | Peking University Shenzhen Hospital | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07329959 | Feb 2026 → Aug 2028 expected | idiopathic pulmonary fibrosis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-DC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07329959 ↗ |
| Known as | chimeric antigen receptor-dendritic cell | “A novel kind of engineered DC, chimeric antigen receptor-dendritic cell (CAR-DC) can reverse the immune suppression in tumor-microenvironment (TME) to enhance anti-tumor therapy.” NCT07504445 ↗ |
| Known as | iCAR-DCs | “CAR technology is applied to generate immunosuppressive CAR-DCs (iCAR-DCs) designed to target FAP, localize to fibrotic lung areas, and attenuate fibrosis without eliciting a...” NCT07329959 ↗ |
| Modality | Cell therapy | “CAR-DC cell therapy” NCT07329959 ↗ |
| Route | Other | “single infusion of autologous FAP-targeted iCDC cells” NCT07329959 ↗ |